LH · Labcorp Holdings Inc.
Price & Indicators
Raw chart and full-history price indicators begin at the captured split on Jul 3, 2023; bars on opposite sides are not compared.
Up next
AI Brief
TL;DR.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EPS non-GAAP | $4.99 | Q2 2026 | — |
|
|
|||
| Adjusted Operating Income non-GAAP | $588.7M | Three Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Operating income 451.6M
+78.1M Amortization of intangibles and other assets (a)
+5.1M Restructuring and other charges (b)
+21.3M Acquisition and disposition-related costs (c)
+11.7M LaunchPad costs (d)
+20.9M Other
+0M TSA reimbursement (e)
= Adjusted Operating Income 588.7M
|
|||
| Adjusted Operating Income (Biopharma Laboratory Services) non-GAAP | $142.2M | Three Months Ended June 30, 2026 | — |
|
|
|||
| Adjusted Operating Income (Diagnostics Laboratories) non-GAAP | $522.6M | Three Months Ended June 30, 2026 | — |
|
|
|||
| AOI as % of Revenue non-GAAP | 15.8% | Three Months Ended June 30, 2026 | — |
|
|
|||
| AOI as % of Revenue (Biopharma Laboratory Services) non-GAAP | 17% | Three Months Ended June 30, 2026 | — |
| AOI as % of Revenue (Diagnostics Laboratories) non-GAAP | 18% | Three Months Ended June 30, 2026 | — |
| Backlog | $8.73B | As of June 30, 2026 | — |
| Free Cash Flow non-GAAP | $313.9M | Three Months Ended June 30, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP Operating Cash Flow 445.5M
-131.6M Capital Expenditures
= Free Cash Flow 313.9M
|
|||
| Next Twelve Months Forecast Backlog Conversion | $2.75B | As of June 30, 2026 | — |
| TTM Book to Bill | 1.03 | As of June 30, 2026 | — |
| TTM Net Orders | $3.32B | As of June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LH
this stock
Labcorp Holdings Inc.
|
$26.22B | +28.4% | +7.2% | 26.7 | 2.6% |
|
TMO
Thermo Fisher Scientific Inc.
|
$217.80B | +1.7% | +14.5% | 31.7 | 1.3% |
|
DHR
Danaher Corp /De/
|
$147.41B | -7.6% | +8.5% | 37.2 | 1.7% |
|
NTRA
Natera, Inc.
|
$45.29B | +36.1% | -2.8% | — | 3.0% |
|
IDXX
Idexx Laboratories Inc /De
|
$44.29B | -18.2% | +10.4% | 39.5 | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
Raw-price comparisons begin at the captured split on Jul 3, 2023; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LH | -0.1% | +15.3% | +13.9% | +4.2% | +28.4% |
| SPY | -0.4% | +2.6% | +10.7% | +2.7% | +12.5% |
| vs SPY | +0.3% | +12.8% | +3.2% | +1.5% | +15.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.